The present study evaluated the placental transfer and amniotic fluid distribution of bupivacaine enantiomers in health pregnant women and in human immunodeficiency virus (HIV)-infected pregnant women receiving epidural anaesthesia for caesarean section.
Introduction
Bupivacaine is a type of local anaesthetic amide frequently used for obstetrical epidural anaesthesia and analgesia. Bupivacaine is appropriate for use in obstetrics since it has low placental transfer [1] [2] [3] [4] [5] .
Bupivacaine has a chiral centre and is available as the racemic mixture of (+)-(R)-bupivacaine and (-)-(S)-bupivacaine enantiomers; (+)-(R)-bupivacaine demonstrated a higher toxicity in the central nervous and cardiovascular systems than (-)-(S)-bupivacaine [6] [7] [8] . Furthermore, the enantioselectivity with respect to pharmacokinetics and protein binding has been demonstrated. The total clearance is higher for (+)-R-bupivacaine than that for (-)-S-bupivacaine in nonpregnant healthy volunteers (33.2 vs. 26.4 l h -1 ) [9] .
A previous study conducted by our research group also showed a higher clearance of (+)-R-bupivacaine when compared to that of (-)-S-bupivacaine (29.0 vs. 25.4 l h -1 ) in healthy pregnant women [3] . Bupivacaine undergoes N-dealkylation dependent on CYP3A4 and ring hydroxylation as its principal metabolism routes, with a low renal excretion of the unchanged form [10, 11] . Bupivacaine is highly bound to plasma proteins (93-97%) [9, 12] , mainly to α1-acid glycoprotein [13] . The decrease in α1-acid glycoprotein levels reported in pregnant women at term affects the unbound fraction of bupivacaine [14] . The placenta serves as the interface between maternal and fetal circulation, providing nutrients and oxygen for fetal development. Although the placenta is viewed as a protective barrier, there are mechanisms of drug transport across this organ that expose the fetus to drugs taken by pregnant women [15] . Several types of pregnant women need to use medications during pregnancy; among them, human immunodeficiency virus (HIV)-infected pregnant women use antiretroviral therapy that helps to avoid the mother-to-child transmission of this virus. HIV treatments include ritonavir and lopinavir, which are >98% bound to plasma proteins, mainly to albumin and α1-acid glycoprotein [16, 17] . Ritonavir is a CYP3A4 inhibitor that reduces the metabolism of concomitantly administered CYP3A4 substrates [18] . Ritonavir increases the bioavailability of the antiretroviral lopinavir predominantly by intestinal CYP3A4 inhibition [19, 20] . Furthermore, the P-glycoprotein (P-gp) inhibition by ritonavir also affects the lopinavir bioavailability [19] . Previous studies have shown that the inhibition of placental P-gp increases the placental transfer of the P-gp substrates and, consequently, exposes the fetus to higher drug concentrations [21, 22] . In this context, it is important to consider the potential drugdrug interactions between antiretroviral therapy and other concomitant drugs taken by HIV-infected pregnant women.
Previous data in healthy pregnant women have shown low placental transfer of both bupivacaine enantiomers [3] [4] [5] . However, the placental transfer and amniotic liquid concentrations of bupivacaine enantiomers in HIV-pregnant women treated with antiretroviral therapy and having submitted to epidural anaesthesia have not been determined. The aim of the present study was to evaluate the influence of lopinavir/ritonavir therapy in HIV-pregnant women on the (+)-R-bupivacaine and (-)-S-bupivacaine plasma concentrations in maternal circulation, the fetal umbilical artery and vein, and amniotic fluid and to compare these data to data from health pregnant women.
Methods

Subjects and clinical protocol
Twelve HIV-infected pregnant women (HIV group) treated long-term (at least 8 weeks) with zidovudine [300 mg twice daily (BID)], lamivudine (150 mg BID), lopinavir (400 mg BID) and ritonavir (100 mg BID) and 12 healthy pregnant women (Control group) were recruited. The study was approved by the Institutional Review Board of the local hospital (Protocol no. 13515/2009), and all patients included in the study signed an informed consent form to participate.
The number of participants was calculated using the PS Power and Sample Size Calculation program (version 2.1.30; Vanderbilt, Nashville, TE, USA). The study power was fixed at 80% with type I error at 5%. A sample of 12 pregnant women per group was calculated to be necessary to detect a difference of 45% in fetal umbilical vein/maternal plasma (mean fetal umbilical vein/maternal plasma considered of 0.42 for bupivacaine as enantiomeric mixture and standard deviation of 0.16) [2] .
The following characteristics were collected for each patient: maternal age, gestational age, maternal weight, height, body mass index, albumin and α1-acid glycoprotein concentrations. Newborn characteristics (weight, height, placental weight, Apgar score and umbilical vein pH) were also obtained.
Racemic bupivacaine was used at a dose of 75 mg and at a concentration of 0.5% based on obstetrical anaesthetic protocols and procedures. After infiltration of the skin with 2% lidocaine, the pregnant women received locoregional epidural anaesthesia consisting of a single dose of the following compounds: 0.1 mg of fentanyl citrate, (0.05 mg/ml Cristália, São Paulo, SP, Brazil), 15 ml of 0.5% bupivacaine hydrochloride with 1:200000 epinephrine (Cristália) and 10 ml of 2% lidocaine hydrochloride without a vasoconstrictor (Cristália). Epidural anaesthesia was administered at the L1-L2, L3-L4 or L4-L5 epidural space. Heart rate and arterial pressure were monitored in each patient throughout the procedure. Prior to the induction of anaesthesia, a maternal blood sample (10 ml) was collected for haematological and biochemical evaluations.
At delivery, simultaneous collection of 10 ml of maternal blood, venous blood and arterial blood from the umbilical cord and an aliquot of 10 ml amniotic fluid (10-20 min after bupivacaine administration) was performed to assess the placental transfer and distribution of bupivacaine enantiomers in these compartments. Laboratory tests were carried out to assess the functional normality of the haematological, renal, hepatic and endocrine systems of the pregnant women. During the caesarean section, the amniotic cavity was identified to enable the puncture to collect amniotic fluid with precautions taken to avoid contamination with maternal blood. The samples were centrifuged at 1800× g for 10 min and the plasma and amniotic fluid supernatants were collected and stored at -70°C. Neonatal evaluation included the time to sustained respiration at 1st and 5th min Apgar score (considered to be abnormal when <7 at the 5th min). The blood from the umbilical cord was employed in blood gas analyses (ABL-5; Radiometer, Copenhagen, Denmark).
Enantioselective analysis of bupivacaine in plasma and amniotic fluid
The enantioselective analysis of bupivacaine was performed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) using a method adapted from a previous study [23] . Briefly, plasma aliquots of 200 μl were spiked with an internal standard (ropivacaine) and added to 2 ml water and 2 ml acetonitrile. The supernatants were separated, added to 0.5 ml aqueous 0.5 mol l -1 NaOH and extracted with 6 ml of nhexane. Amniotic fluid (200 μl) samples were alkalinized and directly extracted with n-hexane. The residues were reconstituted with 125 μl of the mobile phase and 50 μl were injected into the chromatography apparatus. The bupivacaine enantiomers were separated on a Chirex 3020 4.60 × 250 mm chiral column, with a particle size of 5 μm (Phenomenex, Torrance, CA, USA) protected by a 4 × 4 mm CN precolumn, particle size of 5 μm (Lichospher 100; Merck, Darmstadt, Germany) and using as a mobile phase a mixture of hexane: ethanol (80:20, v/v) at a flow rate of 1 ml min -1 .
The mass spectrometry detection system (LC-MS/MS) used for analysis was a Quattro Micro LC triple quadrupole (Micromass, Manchester, UK) equipped with an electrospray interface. The analyses were carried out in the positive ion mode. Tandem mass spectrometry conditions were optimized by direct infusion of standard solutions (400 μg ml The analytical curves built in the concentration ranges of 5-500 ng ml -1 plasma for each enantiomer and 0.02-25 ng ml -1 amniotic fluid for each enantiomer were considered linear. No matrix effect was observed for the two matrices, and the coefficients of variation for intra-and interassay precision and the standard error of intra-and interassay accuracy were <15%. The limits of quantitation (5 ng ml -1 plasma of each enantiomer and 0.02 ng ml -1 amniotic fluid of each enantiomer) were defined as the lowest plasma concentration analysed with a coefficient of variation of <20% and with <15% inaccuracy.
Statistical analysis
The data were analysed using GraphPad Prism software (CA, USA), and the results are reported as medians at the 25th and 75th percentiles. The data were analysed statistically by the Wilcoxon test for paired data, (+)-(R) vs. (-)-(S)-(bupivacaine). The Mann-Whitney test for unpaired data was used to compare the data between the control and HIV group of pregnant women. The level of significance was set at 5% in all tests.
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www. guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY [24] and are permanently archived in the Concise Guide to PHARMA-COLOGY 2017/18 [25, 26] .
Results
Maternal and neonatal characteristics are displayed in Table 1 as medians at the 25th and 75th percentiles. All patients, the 12 HIV-infected pregnant women (HIV group) and the 12 healthy pregnant women (Control group), underwent a caesarean section. Plasma concentrations of α-1-acid glycoprotein were lower for the HIV group, with a median of 40 g dl -1 , when compared with those for the Control group (median of 57.5 g dl -1 ) and with the reference limits for healthy nonpregnant females (52-117 g dl -1 ) [27] . All newborns from both groups had 1st and 5th min Apgar scores ≥7, demonstrating well-being at birth. Only one newborn from the HIV group had an Apgar score of 5 at the 1st min but recovered by the 5th min. The umbilical vein pH was higher than 7.2 for all newborns, except for one newborn in the Control group, whose cord blood pH was 7.06 and 1st min Apgar score was 7, which is identified as fetal acidosis (pH < 7.2) [28] . None of the newborn infants presented diseases diagnosed at birth. Table 2 shows the concentrations of bupivacaine enantiomers in the maternal plasma, fetal umbilical vessels, amniotic fluid and the umbilical/maternal vein ratio, artery/umbilical vein ratio and amniotic fluid/maternal vein ratio in the Control and HIV groups. The data are reported as medians at the 25th and 75th percentiles. The concentrations of the (-)-Sbupivacaine were significantly higher than those of the (+)-(R)-bupivacaine in maternal plasma, fetal umbilical vein and artery in both the HIV and control groups. No significant differences (p < 0.05) between the (+)-(R) and (-)-(S)-bupivacaine enantiomer concentrations were observed in the amniotic fluid in both groups. The median fetal/maternal ratios of (+)-(R)-and (-)-(S)-bupivacaine were 0.25 and 0.25 for the Control group and 0.58 and 0.54 for the HIV group (Figure 1) . We emphasize that the placental transfer in the HIV group increased (~100%) significantly when compared with that in the Control group. Furthermore, (+)-R bupivacaine placental transfer was significantly higher than the (-)-S-enantiomer in the HIV group. No statistically significant differences between (+)-(R)-and (-)-(S)-bupivacaine were observed in regard to umbilical artery/umbilical vein ratios and amniotic fluid/maternal vein ratios in both groups. In addition, no significant differences were observed for these cited ratios (umbilical artery/umbilical vein and amniotic fluid/maternal vein) between the HIV and Control groups.
Discussion
For the first time, this study investigated the influence of long-term HIV treatment with ritonavir, lopinavir, lamivudine and zidovudine on the plasma concentrations Table 2 Concentrations of bupivacaine enantiomers in maternal plasma, fetal umbilical vessels, amniotic fluid and umbilical vein/maternal vein ratio, artery/umbilical vein ratio and amniotic fluid/maternal vein ratio in the control and human immunodeficiency virus (HIV) groups (Table 2 ). This is the first report of bupivacaine enantiomer placental transfer in HIV pregnant women treated with antiretroviral therapy. The placental transfer ratios in health pregnant women (Control group) are in agreement with previous studies from our research team [3] [4] [5] .
Considering that bupivacaine is a substrate of the efflux transporter P-gp that is expressed in the placenta, its placental transfer was low with umbilical cord/maternal blood ratios lower than unity [15, 29] . In a study performed in rats, a reduced hepatobiliary excretion and a higher brain concentration of bupivacaine were observed following the administration of cyclosporine A (a known P-gp inhibitor), showing that P-gp modulates the brain distribution and hepatobiliary excretion of bupivacaine [29] . Ritonavir has been reported to inhibit renal tubular and hepatic P-gp in humans in vivo [30] . In a perfused human placenta study, ritonavir increased the maternal to fetal transfer clearance of the P-gp substrate vinblastine, suggesting the inhibition of this efflux transporter by ritonavir [31] . This evidence suggests that the inhibition of placental P-gp by ritonavir may be involved in the increased (~100%) bupivacaine placental transfer in the HIV group. Ritonavir is also a CYP3A inhibitor that is associated with lopinavir to enhance the oral bioavailability of lopinavir [19] . Bupivacaine is cleared mainly by CYP3A metabolism [11] , so the inhibition of this enzyme could also affect bupivacaine plasma concentrations.
There is little potential for drug-drug interactions between bupivacaine and zidovudine/lamivudine, considering that zidovudine is eliminated via glucuronide metabolism, whereas lamivudine is primarily eliminated renally [32] .
Considering that MRP-1 shares many similarities to P-gp in both substrate specificity and location, and that zidovudine/lamivudine are not reported as MRP-1 inhibitors, zidovudine/lamivudine are probably not also P-gp inhibitors [33] .
There was no significant change in the maternal plasma concentrations of bupivacaine enantiomers between the HIV and Control groups (Table 2) , probably due to long-term ritonavir administration (lopinavir/ritonavir 400/100 mg BID for at least 8 weeks). Previous studies have shown that long-term ritonavir administration to non-pregnant patients results in a balance between CYP3A and P-gp inhibition and induction; nevertheless, the net inhibition effect of ritonavir predominates [30] . However, in pregnancy, this effect could be counterbalanced by the general induction in metabolic enzymes and drug transporters [34] .
Considering that bupivacaine is highly bound to plasma proteins (93-97%) [9, 12] and mainly to α1-acid glycoprotein [13] , its placental transfer also depends on maternal and fetal protein binding differences [35, 36] . However, although P-gp inhibition by ritonavir could explain the increased maternal to fetal transfer in the HIV group, there is another more reasonable explanation for this phenomenon. Since bupivacaine is a small molecule (molecular weight of 288.4 g mol -1 ) with high lipophilicity (log D of 2.46), it is believed that bupivacaine crosses the placenta by passive diffusion rather than active transport. As gestation progresses, α1-acid glycoprotein plasma concentration decreases [37] . Since only protein-unbound drugs are available to cross the placenta, the lower α1-acid glycoprotein levels in pregnant women at term implicate a higher unbound fraction of bupivacaine and, consequently, in a higher placental transfer [38, 39] . In this context, Tsen et al. [37] demonstrated that an increase in the free fraction of bupivacaine was observed with increasing gestational age and with decreasing α-1 acid glycoprotein plasma concentration [37] . The fetal α-1 acid glycoprotein plasma concentrations increase with gestational age but did not reach maternal concentrations, corresponding to 30-40% of mother concentration at delivery [40] . The low placental transfer ratio of bupivacaine could be explained by the relatively reduced fetal α-1 acid glycoprotein plasma concentrations. The tendency of lower α1-acid glycoprotein plasma levels detected in the HIV group when compared to those in the Control group (HIV group median 40 mg dl -1 vs. Control group median 57.5 mg dl -1 ) could explain the higher placental transfer of bupivacaine enantiomers, as discussed earlier.
We did not find a reasonable explanation for the higher decrease in α1-acid glycoprotein plasma levels in the HIV group when compared with that in the Control group. The α1-acid glycoprotein is a so-called acute-phase protein that is sensitive to stressful situations, including surgical trauma, such as a caesarean section, and may be altered by various disease states [41, 42] . After a major surgical procedure, α1-acid glycoprotein plasma levels decrease during the first few hours, and this decrease is followed by a progressive increase in the next few days [42] . Nonetheless, both groups were submitted to similar surgical conditions. The addition of a competing α1-acid glycoprotein could also increase the free fraction of the drug. Lopinavir is highly bound to plasma proteins (> 99%) and is characterized by Figure 1 Influence of lopinavir/ritonavir treatment in placental transfer of bupivacaine enantiomers in human immunodeficiency virus (HIV)-infected pregnant women. Box plots display the 25th, median and 75th percentiles as horizontal lines on a bar; whiskers above and below the box indicate the 95th and 5th percentiles. *P < 0.05 Wilcoxon test for paired data: (+)-R-bupivacaine vs. (-)-Sbupivacaine. #P < 0.05 Mann-Whitney for non-paired data: HIV vs. Control saturable binding to α1-acid glycoprotein [17] . Nevertheless, the displacement of bupivacaine by lopinavir in the α1-acid glycoprotein binding site is an unlikely mechanism because bupivacaine binds with high-affinity to this protein [13] .
Fetal acidaemia increases the placental transfer of bupivacaine [43] . Bupivacaine is a basic molecule (pKa 8.1) that can become trapped in its ionized form on the fetal side of the placenta in an acidic environment. Nevertheless, the pH values for both groups (HIV and Control groups) were higher than 7.2, except for one newborn from the Control group with a pH of 7.06. Different from the median placental transfer of the Control group (0.25), the placental transfer in this patient was 0.59 and 0.52 for R-(+)-bupivacaine and S-(-)-bupivacaine, respectively. In this case, the lower pH environment of the fetus may have been the cause for the higher placental transfer.
Our study demonstrates low concentrations of bupivacaine in fetal compartments (umbilical artery, umbilical vein and amniotic fluid) when compared with maternal plasma concentrations in both groups (HIV and Control). Fetal metabolism was assessed using umbilical artery/umbilical vein ratios of the bupivacaine enantiomers. The ratios were 0.65 and 0.66 for (+)-(R)-bupivacaine and (-)-(S)-bupivacaine, respectively, in the Control group and 0.61 and 0.71 for (+)-(R)-bupivacaine and (-)-(S)-bupivacaine, respectively, in the HIV group. These low ratios demonstrate a low metabolic rate in the fetus. A previous study investigating healthy pregnant women demonstrated similar ratios [5] . This result may be related to the low expression of CYP3A4 in the fetal liver responsible for the metabolism of bupivacaine [44] . Amniotic fluid/maternal vein ratios were also low for the HIV group (0.010 for (-)-(S)-bupivacaine and 0.008 for (+)-(R)-bupivacaine) and the Control group (0.0215 for (-)-(S)-bupivacaine and 0.0185 for (+)-(R)-bupivacaine), explained by high binding to maternal α1-acid glycoprotein, as discussed earlier. The low concentrations of bupivacaine in the amniotic fluid indicate that this sample was not appropriate for pharmacokinetic studies of this drug [45] . Considering that the amniotic fluid in the third trimester of pregnancy is a product of fetal urinary output, the bupivacaine concentration in this fluid is a direct result of fetal metabolism of this drug. Furthermore, bupivacaine is not predominantly eliminated in urine (<15%), a fact that limits its distribution in the amniotic fluid.
According to previous studies investigating healthy pregnant women [4, 5] , no statistically significant differences were seen between (-)-(S)-and (+)-(R)-bupivacaine placental transfer (0.25 vs. 0.25) in the Control group. However, statistically significant differences were observed between bupivacaine enantiomers (0.54 vs. 0.58) in the HIV group. Although there are no data regarding the CYP isoforms involved in the metabolism of individual bupivacaine enantiomers in human liver microsomes, it is probable that the metabolism of (-)-(S)-bupivacaine is more dependent on CYP3A4 and consequently is more affected by ritonavir.
In conclusion, this study supports that the placental transfer of both bupivacaine enantiomers was 100% higher in HIV-pregnant women treated with lopinavir/ritonavir when compared with that in healthy pregnant women receiving epidural anaesthesia for caesarean section. The higher exposure of the fetus to both bupivacaine enantiomers may be due the lower α1-acid glycoprotein mother plasma concentrations and the probable increase in the unbound fraction of bupivacaine.
